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ABSTRACT
In experimental mouse models of cancer, increasingly compelling evidence point toward a contribution of
tumor associated macrophages (TAM) to tumor lymphangiogenesis. Corresponding experimental
observations in human cancer remain scarce although lymphatic metastasis is widely recognized as a
predominant route for tumor spread. We previously showed that, in malignant tumors of untreated breast
cancer (BC) patients, TIE-2-expressing monocytes (TEM) are highly proangiogenic immunosuppressive
cells and that TIE-2 and VEGFR signaling pathways drive TEM immunosuppressive function. We report
here that, in human BC, TEM express the canonical lymphatic markers LYVE-1, Podoplanin, VEGFR-3 and
PROX-1. Critically, both TEM acquisition of lymphatic markers and insertion into lymphatic vessels were
observed in tumors but not in adjacent non-neoplastic tissues, suggesting that the tumor
microenvironment shapes both TEM phenotype and spatial distribution. We assessed the lymphangiogenic
activity of TEM isolated from dissociated primary breast tumors in vitro and in vivo using endothelial cells
(EC) sprouting assay and corneal vascularization assay, respectively. We show that, in addition to their
known hemangiogenic function, TEM isolated from breast tumor display a lymphangiogenic activity.
Importantly, TIE-2 and VEGFR pathways display variable contributions to TEM angiogenic and
lymphangiogenic activities across BC patients; however, combination of TIE-2 and VEGFR kinase inhibitors
abrogated these activities and overcame inter-patient variability. These results highlight the direct
contribution of tumor TEM to the breast tumor lymphatic network and suggest a combined use of TIE-2
and VEGFR kinase inhibitors as a therapeutic approach to block hem- and lymphangiogenesis in BC.
Abbreviations: ANG-1–4, angiopoietins 1–4; BC, breast cancer; BEC, blood endothelial cells; BMDC, bone marrow-
derived cells; EC, endothelial cells; HUVEC, Human Umbilical Vein Endothelial Cells; LEC, lymphatic endothelial cell;
LYVE-1, lymphatic vessel endothelial hyaluronan receptor; PlGF, Placenta Growth Factor; PROX-1, prospero-related
homeobox 1; SMA, Alpha-smooth muscle actin; TAM, tumor associated macrophages; TEM, TIE-2-expressing mono-
cytes; TIE-2, tunica interna endothelial cell kinase; TNF-a, Tumor Necrosis Factor; VEGF, Vascular endothelial growth
factor; VEGFR, Vascular endothelial growth factor receptor
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Introduction
Several lines of evidence suggest that the recruitment of bone
marrow-derived cells (BMDC) to malignant tumors is crucial for
the angiogenic switch and metastasis.1 BMDC circulating in the
peripheral blood can differentiate within the tumor microenvi-
ronment into tumor-associated macrophages (TAM) which are
believed to exert both protumoral and tumoricidal functions. In
this respect, TAM appear to be responsible for conﬂicting roles
of the immune system in cancer.2 This functional dichotomy
probably reﬂects TAM plasticity and notably their adaptation to
a local tumor microenvironment, which contains a complex
network of proinﬂammatory and angiogenic mediators.3-5
TAM are proposed to carry out their protumoral activity via
three different mechanisms; (i) release of angiogenic factors that
trigger an increase in tumor vasculature via EC sprouting from pre-
existing vessels, (ii) secretion of proteases that mediate breakdown
of the extracellular matrix, a key step in the metastatic spread of
tumor cells and (iii) secretion of immunosuppressive mediators
that impair T-cell cytotoxic activity and proliferation.4 The contri-
bution of TAM to tumor angiogenesis has been investigated as a
potential target for cancer therapy.3 Recent evidence suggests that,
in addition to their hemangiogenic activity, TAM also participate
in tumor lymphangiogenesis.6, 7 Unfortunately, investigations into
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the role of TAM in tumor lymphangiogenesis are complicated by
overlapping phenotypes with other macrophages8 and EC, as well
as phenotype plasticity.9 In a murine model of cancer, TAM were
found to carry the canonical lymphatic marker LYVE-1 (lymphatic
vessel endothelial hyaluronan receptor).10-12 Studies in murine
models of inﬂammation13,14 have conﬁrmed the trans-differentia-
tion ofmacrophages into EC and their expression of other canonical
lymphatic markers such as VEGFR-3,15,16 prospero-related
homeobox 1 (PROX-1) or Podoplanin.12
De Palma and coworkers identiﬁed a subset of TAM
expressing the tunica interna endothelial cell kinase (TIE-2 or
CD202b), a receptor tyrosine kinase (RTK) expressed by
EC.17,18 TEM have been documented in murine and human
peripheral blood19,20 as well as in tumor tissues where they act
as paracrine inducers of angiogenesis.21 TEM were found to
account for most, if not all angiogenic activity of BMDC in a
murine experimental model of cancer.22 TIE-2 is a RTK that
binds angiopoietins 1–4 (ANG-1–4) and is critically involved
in vascular embryogenesis and adult angiogenesis.23 In mouse
models of BC, TIE-2 signaling upon ANG-2 binding was pro-
posed to contribute to tumor growth, metastasis and TEM
angiogenic activity mice.24,25 We reported that in human BC
TEM are angiogenic26 and suppressive cells.27 Higher TAM
number was associated with a reduced relapse-free and overall
survival,28 a higher tumor grade, estrogen and progesterone
receptors negativity, HER-2 positivity and a basal phenotype.29
However, corresponding evidence for the contribution of TAM
or TEM to human cancer lymphangiogenesis remains scarce. To
the best of our knowledge, observations are limited to cervical squa-
mous carcinoma where TAM expressing VEGFR-3 have been
linked to the density of lymphaticmicrovessels.30 Herein, we exam-
ined the contribution of TEM to tumor lymphangiogenesis in
human invasive breast carcinoma. We report that TEM display a
lymphatic endothelial cell (LEC) phenotype and associate with
tumor lymphatics, but not with lymphatics of adjacent non-neo-
plastic tissue where they show drastically reduced TIE-2 expres-
sion. Furthermore, we show that tumor TEM are lymphangiogenic
in vitro and in vivo. TEM hem- and lymphangiogenic activities are
controlled by both TIE-2 and VEGFR kinase activities as shown by
using speciﬁc kinase inhibitors of these receptors. In light of the
crucial role of the lymphatic system in BC metastasis,31 a better
understanding of the signaling pathways controlling TEM angio-
genesis may enable the design of efﬁcient anti-angiogenic therapies.
Results
TEM can be identiﬁed in breast tumors solely based on
CD14 immunostaining
The presence of TEM within the haematopoietic inﬁltrate of
human solid tumors has been demonstrated in various malig-
nant human tumors, including BC.21 However, an in-depth
characterization of TEM present in breast tumor tissues is
missing. We determined by FACS the frequency of TEM in
freshly dissociated primary tumors of BC patients (n = 10) who
were untreated at time of surgery (clinicopathological charac-
teristics of all 31 patients from this study are listed in Table 1).
Fresh tumor specimens were collected from the viable (non-
necrotic) tumor center and excluded most of the peritumoral
non-neoplastic tissues (see material and methods). Tumor
specimens were freshly dissociated with collagenase and TEM
were characterized by FACS using a combination of speciﬁc
antibodies for the pan-haematopoietic marker protein tyrosine
phosphatase receptor type C (CD45), the myeloid cell-speciﬁc
leucine-rich glycoprotein (CD14), integrin a M (CD11b) and
TIE-2, as previously established21 (see supplemental material
and method section and Fig. S1B). We observed that TEM rep-
resent a substantial fraction of the haematopoietic inﬁltrate
(22% § 2.7% of CD45C leukocytes), comparable to the fre-
quency of CD8C T lymphocytes (24% § 10%). Using confocal
microscopy and ﬂow cytometry, we observed that TEM in
breast tumor tissues are CD14C, CD45C, CD11c-, HLA-DRC,
CD68C (Fig. S1), TIE-2C (Figs. 1A, S1B and S2A). In addition,
TEM were heterogeneously distributed within the tumor. They
were almost excluded from the peritumoral area (where CD3+
and CD45+ cell counts were higher) and enriched in speciﬁc
area of the tumor center and tumor invasive edges (Fig. S3C).
Further, confocal microscopy analysis revealed that the vast
majority ( 95%) of CD14C cells express both TIE-2 and
VEGFR-1 (Figs. 1A, 1B, S1 and S2A). A quantitative analysis of
CD14, TIE-2 and VEGFR-1 expression levels was carried out
on immunoﬂuorescence images (Fig. 1A, control stainings and
HE stainings are shown in Figs. S2B and C) and a Spearman’s
rank correlation coefﬁcient was calculated (Methods) for indi-
vidual confocal microscopy ﬁelds (n = 6 § 2 for each patient)
across all patients (n = 11). A high Spearman’s rank correlation
was found between CD14 and TIE-2 expression levels (r = 0.79
§ 0.05, Fig. 1B), as well as CD14 and VEGFR-1 levels (r = 0.80
§ 0.05, Fig. 1C), indicating that CD14, VEGFR-1 and TIE-2
expression is phenotypically linked. In order to validate our
methodology, the correlation between VEGFR-1 and TIE-2
expression levels was considered as a positive control (r = 0.88
§ 0.05, Fig. S3A) since these two receptors are known to be co-
expressed by blood endothelial cells (BEC).32 As previously
described,21 TEM did not express detectable levels of the plate-
let endothelial cell adhesion molecule (CD31, Fig. 4A), a proto-
typical BEC marker and, accordingly CD14 and CD31
expression levels did not correlate (Fig. S3B). Finally, TEM
Table 1. Clinical and pathological features of tumors and patients (n = 31).
Patient characteristics % (nb of patients)
Age (median, range) years
<50 52 (16)
50 48 (15)
Surgical treatment
Mastectomy 39 (12)
Tumorectomy 61 (19)
Lymph node status
Negative 61 (19)
Positive 39 (12)
Tumor
T1 48 (15)
T2< 3cm 52 (16)
Histology
Ductal 81 (25)
Lobular 13 (4)
Others 6 (2)
Grade
I 13 (5)
II 42 (13)
III 45 (14)
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were found to express comparable levels of TIE-2 relative to
tumor blood vessels (Fig. 1D).
These results suggest that in human BC tissues TEM can be
reliably identiﬁed using CD14 as a single marker, based on the
observation that CD14 expression correlates with that of TIE-2
and VEGFR-1 (Figs. 1B and C).
TEM are highly angiogenic cells promoting tumor growth
In BC, more than 95% of CD14C cells are TEM (i.e. express
TIE-2, Figs. 1A, 1B, S1 and S2A). Importantly, we observed
that CD14C cells from non-neoplastic tissues adjacent to the
tumor (Fig. 1E) show low levels of TIE-2 and VEGFR-1 expres-
sion suggesting that the tumor microenvironment markedly
shapes TEM phenotype. In BC, CD14 expression levels were
heterogeneous and not signiﬁcantly different in the tumor cen-
ter or the tumor leading edges (n = 6, p > 0.05 and Fig. S3C).
Further, CD14 levels correlated with VEGFR-1 and TIE-2
expression levels in these two tumor zones (r = 0.79 § 0.05; r
= 0.79 § 0.05, respectively).
However, this tumor TEM phenotype may not hold true for
other types of cancer where TIE-2 was only detected in 37%–72%
of all CD14C cells.21 We have recently shown that TIE-2 and
VEGFR-1 co-expression control TEM angiogenic activity.26 Since
CD14 expression correlates with the expression of TIE-2 and
VEGFR-1 (Figs. 1B and C), monitoring CD14 inﬁltrate across BC
tissues may be sufﬁcient to evaluate their angiogenic activity. Con-
sistent with this observation, we found that CD14 expression levels
per mg of tumor tissue correlated with the size of the tumor26 sug-
gesting that TEM contribute to tumor growth by inducing tumor
vascularization. In order to check this hypothesis, we used a
patient-derived BC xenograft (PDX) mouse model. Three months
post-tumor engraftment, pairs of PDX mice engrafted with the
same primary patient tumor fragments and showing comparable
tumor size were selected. TEM were isolated by CD14 immuno-
magnetic selection from autologous primary tumors. Tumor TEM
or as a control magnetic beads only, were injected in the tumor
vicinity of each mouse. Two weeks later, the mice were sacriﬁced
and the tumor volume and the total surface area covered by blood
vessels in the tumor quantiﬁed. Mice injected with TEM showed a
dramatic increase of their tumor size and total blood vascular net-
work relative to control mice (Fig 2) showing that tumor TEM sup-
port tumor growth and vascularization.
In human breast tumors, TEM express LEC markers
In various murine experimental models of cancer, macro-
phages have been reported to display LEC traits.15,33 To date,
Figure 1. In human breast tumors, TEM can be identiﬁed solely based on CD14 immunostaining. (A) Immunoﬂuorescence staining and confocal analysis of human BC
tumor sections showing CD14, TIE-2 and VEGFR-1 triple positive cells. Representative image from 16 patients; (B) CD14 and TIE-2 expression correlation analysis. The dot
plot (left panel) represents all tiles for one representative image; the box plot (right panel) shows the Spearman’s rank correlation coefﬁcient (r) for CD14 and TIE-2
expression in 11 patients. In the dot plot, 54% of CD14C tiles and 70% of TIE-2C tiles were above the threshold. 100% of CD14C tiles were TIE-2C which means that the
high correlation (r = 0.844) applied to all CD14C tiles; (C) CD14 and VEGFR-1 expression correlation analysis for 11 patients. In the dots plot, 55% of CD14C tiles and 75%
of VEGFR-1C tiles were above the threshold. 100% of CD14C tiles are VEGFR-1C which means that the high correlation (r = 0.852) applied to all CD14C tiles; (D) Example
of TIE-2 expression in TEM, clusters of BEC (arrow heads) and blood vessels (right panel) shown in confocal microscopy images of BC sections. TEM and blood endothelial
structures were stained with CD14 and CD31, respectively; (E) Example of immunoﬂuorescence labeling of CD14, VEGFR-1 and TIE-2 in sections containing non-neoplastic
breast tissue adjacent to tumor tissues. CD14C cells (arrows) are VEGFR- and TIE-2-. Non-neoplastic (panel E) and tumor tissue (panel A) were stained and imaged simulta-
neously under the same conditions and thus intensities of the expression of TIE-2 and VEGFR-1 signals can be compared. Representative images from four patients. Scale
bars: 25 mm.
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the corresponding evidence for the expression of a LEC phe-
notype in human TAM has been scarce. This prompted us
to examine the expression of LEC markers, as well as the
VEGFR co-receptors Neuropilin-1 and Neuropilin-2,34 on
TEM associated with BC tissues. Confocal microscopy analy-
sis of breast tumor sections revealed that TEM express the
canonical lymphatic markers VEGFR-2, VEGFR-3, LYVE-1,
Podoplanin and PROX-1 (Fig. 3A and S4). However, while
the expression of Podoplanin, VEGFR-3 and LYVE-1 is
homogeneous, VEGFR-2 and PROX-1 expression displayed
a higher degree of variability in TEM (Fig. 3A). When ana-
lyzing for VEGFR co-receptor expression, we found expres-
sion of Neuropilin-2 but no detectable expression of
Neuropilin-1 (Fig. 3B). The expression of the VEGFR-2,
VEGFR-3, LYVE-1, Podoplanin, PROX-1 and Neuropilin-2
suggests a putative role for TEM in cancer lymphangiogene-
sis, in addition to their characterized proangiogenic activity
(Fig. 2 and 26). Since lymphatics express very low levels of
CD31 in contrast to blood vessels, the absence of observable
CD31 expression on TEM (vide supra) is also consistent
with a lymphatic phenotype. The majority of TEM (LYVE-
1C/PodoplaninC/VEGFR-3C/PROX-1C) were cells scattered
across the tumor with no apparent degree of structural orga-
nization and displayed variable expression levels for lym-
phatic markers (Fig. 3A). Some TEM were also found to
form small aggregates of various shapes and sizes (10–50
cells, Fig. 3C and Fig. S5A). In the latter case, CD14 expres-
sion was high and showed good correlation with lymphatic
marker expression (Fig. S5B), suggesting that these aggre-
gates are composed of a homogeneous population. We con-
ﬁrmed TEM lymphatic phenotype by gene expression
analysis of TEM (CD14C, CD45C) sorted ex vivo from colla-
genase-dissociated breast tumors. PROX1 expression was
assessed by RT-PCR in eight independent samples of 10-cell
aliquots sorted from four distinct tumors. A representative
example of gene expression proﬁle is shown in Fig. 3D.
PROX1 was expressed in the four tumors and in 75% of the
cell aliquots (24 positive samples/32 samples in total)
examined.
Finally and importantly, the observation that CD14C cells
from non-neoplastic tissues adjacent to the tumor did not express
detectable levels of Podoplanin and VEGFR-3 (Fig. 3E) further
supports a phenotypic switch of CD14C cells in the tumor micro-
environment. Finally and consistent with these ﬁndings, when we
expressed TEM angiogenic activity as the percentage of tumor
area covered by CD14C cells multiplied by the mean ﬂuorescence
intensity of CD14C cells, we observed a correlation of this angio-
genic activity with the ratio of CD14 to lymphocyte inﬁltrate
(Fig. S3D). This ratio reﬂects the balance of TEM immunosup-
pression27 to effective antitumor immune response.35
Figure 2. TEM are highly angiogenic cells supporting breast tumor growth. Quantiﬁcation of the volume and of the vascularization of PDX tumors two weeks post-injec-
tion in the tumor vicinity of autologous tumor TEM (Tumor TEM mice) or buffer and magnetic beads (No cell, control mice). Pairs of mice showing comparable tumor vol-
ume have been used. Scale bar: 50 mm.
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TEM accumulate in tumor areas that are enriched in small
immature blood vessels
Because TEM isolated from BC tissues are highly proangiogenic
(Fig. 2 and 26), we examined the spatial relationship between
TEM distribution and the tumoral vascular network. To this
end, blood vessels and TEM were identiﬁed in breast tumor
cryosections by CD31 and CD14 dual immunoﬂuorescence
using confocal microscopy. The CD31C structures were catego-
rized into small and large vessels based on their surface area.
Of the total vessel area, 88% were either small or large vessels
present in similar proportions (53% and 47% respectively).
Blood vessels of intermediate size accounted for the remaining
12% of the total vessel area and were excluded from the analy-
sis. Small vessels, in contrast to large vessels, failed to stain for
a-smooth muscle actin (SMA) and represent immature vessels
(Fig. 4C). Small vessels displayed a chaotic architecture
(Fig. 4A, ﬁrst panel) and likely represent newly formed blood
vessels36 while large vessels were organized in a more struc-
tured vascular network (Fig. 4A, second panel). Using a modiﬁ-
cation of the quantiﬁcation method used for the determination
of expression levels correlation (Materials and Methods) the
proximity of TEM with large or small vessels was examined in
945 ﬁelds. We found a markedly higher spatial relationship
(p  0.001) between TEM and small vessels compared to large
vessels (Fig. 4B). The trend showing association of TEM with
small vessels was also observed in zones where both types of
vascular networks overlap (Fig. 4A, third panel). Thus, TEM
are highly proangiogenic monocytes (Fig. 2) enriched in tumor
areas of intense neo-vascularization (Fig. 4B).
TEM are found associated with lymphatic vessels
We also examined TEM distribution relative to lymphatic vessels.
Since TEM and LEC seem to share canonical lymphatic markers
(Fig. 3A), CD14 labeling was used to discriminate between cells of
myeloid and endothelial character. Triple immunostaining experi-
ments using CD14- and PROX-1-speciﬁc antibodies in combina-
tion with either LYVE-1 or Podoplanin were carried out and the
sections analyzed by confocal microscopy. TEM were inserted into
circular or elongated structures composed of a single layer of over-
lapping cells, an architectural feature characteristic of lymphatic
vessels (Fig. 5A, Figs. S6A and B).34 These LYVE-1C/PodoplaninC/
PROX-1C/CD14- (Fig. 5A, Figs. S6A and B) structures appeared
mostly VEGFR-3C and Neuropilin-2C but TIE-2low (Fig. S6A),
with insertion of TEM expressing variable levels of CD14, TIE-2
and LEC markers. It is worth noting that few intact lymphatic
Figure 3. TEM carry a lymphatic phenotype in human breast tumor. The expression of (A) the lymphatic markers VEGFR-2, LYVE-1, VEGFR-3, Podoplanin, and PROX-1 and
(B) the VEGFR co-receptors Neuropilin-1 and Neuropilin-2 was examined in breast tumor sections by confocal microscopy. Representative images from minimum ﬁve
patients; (C) Some TEM formed small cell aggregates (10–100 cells); (D) PROX1 expression analysis was performed by RT-PCR from mRNA isolated from mouse cells (nega-
tive control), LEC in culture (positive control) and from TEM (CD14CCD45C cells) sorted by ﬂow cytometry from dissociated breast tumor. One representative gene expres-
sion proﬁle from 10-cell samples from one patient is shown out of 32 cell samples from four patients (8 samples/patient of 10 cells each); (E) Immunoﬂuorescence labeling
in sections of non-neoplastic breast tissue adjacent to tumor tissues shows no detectable expression of Podoplanin and VEGFR-3. Non-neoplastic (panel E) and tumor tis-
sue (panel A and C) were stained and imaged simultaneously under the same conditions and thus intensities of the expression of Podoplanin and VEGFR-3 signals can be
compared. Scale bars (A-C and E): 25 mm, (A) higher magniﬁcation, scale bar: 10 mm.
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structures were present in the tumor sections investigated and that
most TEM were observed either scattered across the tumor or
aggregated into small clusters (Figs. 3A and 3C). The observation
that TEM are associated with tumor lymphatics may reﬂect either
an ongoing transmigration of TEM through the lymphatic endo-
thelium, a stable association of TEM with lymphatics. Two lines of
evidences suggest that TEM are indeed inserted into lymphatics.
First, TEM consistently display an elongated shape when observed
in lymphatics (Fig. 5A), contrasting with their round and bulky
shape when aggregated into clusters (Fig. 3C) or scattered across
the tumor (Fig. 3A). Second, co-staining with the endothelial cell-
speciﬁc adherens junction protein VE-Cadherin shows a continu-
ous expression along the lymphatic structure, including the site of
TEM interaction (Fig. 5B). Comparable observations were made
for BMDC incorporated into lymphatics in mouse experimental
model of cancer12 andmay reﬂect a similar cellular process.
In order to investigate the relevance of the association of
TEM with lymphatic vessels, we examined sections of non-neo-
plastic breast tissue adjacent to tumor tissues within the surgi-
cal margin in the same patients (n = 7). We observed that
PodoplaninC and LYVE-1C lymphatic vessels at the tumor
periphery did not express any detectable levels of CD14
(Fig. 5C and Fig. S6C) although CD14CTIE-2- myeloid cells
were present in these areas (Fig. 1E). These observations sug-
gest that TEM association with lymphatics occurs speciﬁcally
within the BC microenvironment. Because BC spreads primar-
ily via lymphatics and regional lymph nodes are usually the ﬁrst
metastatic sites to be involved,31 we examined the relationship
between lymph node status and TEM association with tumor
lymphatics. Interestingly, all patients (100%) with metastasis to
the LN (n = 10 ) were found to have TEM associated with
tumor lymphatics whereas this was only the case for 57% of the
patients (n = 12 ) without LN metastasis. These observations
suggest that TEM associated to lymphatics may contribute to
the spreading of tumor cells to proximal LN through a yet
unknown mechanism.
TEM isolated from human breast tumors are
lymphangiogenic
The observed TEM association with cancerous lymphatic struc-
tures (Fig. 5A, B and Figs. S6A, B) together with their expression
of lymphatic markers (Figs. 3A and B) strongly suggest a role for
TEM in tumoral lymphangiogenesis. TEM lymphangiogenic
activity was assessed by the in vivo corneal vascularization assay.
The cornea is avascular and the formation of blood or lymphatic
vessels sprouting from the peripheral limbal vasculature can be
taken as a qualitative measure of TEM angiogenic and lymphan-
giogenic activity, respectively.37 Due to the limited number of
TEM that can be isolated from primary BC tissues, mice were
preferred to rabbits for corneal vascularization assays because of
the smaller size of their eyes. Immunocompromised NOD-scid
IL2Rgnull mice were used to prevent the rejection of patient TEM
by the mouse immune system. Mouse corneas were injected with
CD14C cells immunoselected from freshly dissociated BC tissue
and 3–4 weeks later sagittal cryosections of the mouse eyes were
stained with antibodies speciﬁc for LYVE-1 to assess de novo
growth of lymphatic vessels. The surface area covered by lym-
phatic vessels was > 800-fold higher in the cornea of mice
injected with TEM relative to the one of mice injected with buffer
and beads only (p < 0.01, Fig. 6A). These results indicate that
tumor TEM induce corneal lymphatics vascularization i.e., are
lymphangiogenic cells. Consistent with these observations, the
majority of TEM sorted from dissociated breast carcinoma by
ﬂow cytometry (CD45C, CD14C) express VEGF-A, -C and -D
(Fig. 6B). Thus, in addition to their hemangiogenic activity
(Fig. 2 and26), TEM isolated from human breast tumor tissues
are lymphangiogenic in vivo.
Figure 4. In BC tumors, TEM are associated with patchy and poorly structured blood vessels. (A) TEM spatial relationship to small and large vessels. Scale bar: 100 mm,
representative image from 16 patients; (B) TEM were found located in the proximity of small blood vessels, rather than large vessels (t test,  p  0.0001); (C) In BC
tumors, the vast majority of large vessels (arrow heads) stain positive for a-SMA while small vessels do not. Scale bar: 50 mm.
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TIE-2 and VEGFR kinase activities contribute to TEM hem-
and lymphangiogenic activities
We next examined the contribution of TIE-2 and VEGFR
kinase activities to TEM angiogenic activity. To this end,
TEM isolated from freshly dissociated breast carcinoma
were treated for 2 h with kinase inhibitors speciﬁc for TIE-
2 and VEGFR-1–3, extensively washed and then added to
human umbilical vein endothelial cells (HUVEC)- or LEC-
covered microcarrier beads embedded in a 3D ﬁbrin gel
(Supplemental Material and Methods). In the absence of
inhibitors, both HUVEC and LEC were found to form
sprouts when co-cultured with TEM (Fig. 6C), conﬁrming
TEM dual hem- (Fig. 2 and26) and lymphangiogenic
(Fig. 6A) activities. Individually, TIE-2 or VEGFR inhibitor
treatments showed a highly variable effect on TEM heman-
giogenic and lymphangiogenic activities among different
patients (Fig. 6C). However, TEM-induced hemangiogenic
and lymphangiogenic activities were almost completely
impaired in all patients by a combined treatment. These
observations indicate that the dual hem- and lymphangio-
genic activities are under the control of a synergistic action
between TIE-2 and VEGFR pathways.26 Furthermore, this
synergy shows inter-patient variability, but a combined
blockade of TIE-2 and VEGFR kinase activities shows a
consistent effect, overcoming patient heterogeneity.
Discussion
We show in this study that the levels of CD14 expression cor-
relates with that of TIE-2 and VEGFR-1 for TEM in primary
tumors of untreated BC patients (Figs. 1B and C). Since we
show that the expression levels of TIE-2 and VEGFR-1 reﬂect
TEM proangiogenic activity,26 we thus propose that CD14 can
be considered an indicator of TEM-induced angiogenic activ-
ity in BC. Furthermore, we show that TEM account for the
majority (> 95%) of the CD14highCD11bCHLA-DRC cells
(Figs. 1 and S1) which constitute a substantial portion (>
20%) of the CD45C inﬁltrate in breast carcinomas. In this
respect, our results contrast with reports suggesting that
CD14highCD11bCHLA-DRC cells account for only 4% of the
CD45C population in breast carcinomas.38 While Coussens
and coworkers did not investigate TIE-2 expression,38 this dis-
crepancy may be due to a sampling artifact,39 and more pre-
cisely the proximity with the resection margins. Our results
are based on the analysis of viable center of tumors, where the
density of total haematopoietic inﬁltrate might be lower, as
suggested by a low T-cell inﬁltration.
Importantly, we show that in breast tumors, TEM systemati-
cally express lymphatic markers (Figs. 3A and S4) as well as
Neuropilin-2 (Fig. 3B), VEGF-A, -C and -D (Fig. 6B). Based on
this observation, we propose that in BC, TEM can be discrimi-
nated from LEC solely based on their CD14 expression. The
Figure 5. In BC tumors, TEM are associated with lymphatic structures. (A) TEM (arrow, CD14CLYVE-1CPROX-1C cells) were associated with lymphatic vessels (arrowhead,
CD14-LYVE-1CPROX-1C cells); (B) Immunoﬂuorescence labeling of TEM-containing lymphatics (arrows) with VE-cadherin; (C) Immunoﬂuorescence labeling in sections of
non-neoplastic breast tissue adjacent to tumor tissues shows no TEM association with LYVE-1C lymphatic vessels. Scale bars: 25 mm. Representative image from seven
patients.
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inﬁltration of tumor tissues by macrophages displaying canoni-
cal LEC markers has been reported in murine experimental
models of cancer.15,33 To our knowledge, there is only one com-
parable observation in humans describing that TAM expressing
VEGFR-3, VEGF-C and -D are present in cervical squamous
carcinomas.30
The insertion of BMDC into lymphatic vessels was reported
in murine models of inﬂammation10,12,15,40,41 or cancer11 in
mice. To the best of our knowledge, our results support for the
ﬁrst time that TEM have a similar behavior in human cancer.
The signiﬁcance and the mechanism of TEM association with
lymphatics predominantly in patients showing regional LN
metastasis remain to be elucidated. Regional lymph node status
is the single most important prognostic factor in BC and patients
with axillary metastasis at the time of diagnosis have a much
worse prognosis than those without metastasis. The extent of
sentinel LN lymphangiogenesis and lymphatic tumor invasion
was correlated with non-sentinel LN metastasis in BC
patients.42,43 Thus, given the lymphangiogenic activity of BC
TEM and the role of lymphatics in metastasis,31 it is reasonable
to suggest that TEM not only participate to cytokine-mediated
lymphangiogenesis (44 and Fig. 6B) but also contribute to the
spreading of tumor cells to regional LN. Indeed, the observed
association of tumor TEM with tumor lymphatics (Figs. 5A and
B) and LN lymphangiogenesis7 prior to the onset of LN metasta-
sis align wells with the concept of a creation of a premetastatic
niche by the primary tumor.7,45 Breast tumors were reported to
contain few intratumoral lymphatics46,47 and hyperplasia of pre-
existing lymphatic vessels, rather than de novo formation of lym-
phatic vessels was reported to be associated with metastasis in
BC.48,49 We make the assumption that TEM might contribute to
lymphatics hyperplasia through their association with lymphatic
vessels (Fig. 5), their lymphangiogenic activity and their aptitude
to produce VEGF-C and VEGF-D (Fig. 6).
The insertion into lymphatics of BDMC displaying a
LEC phenotype was observed in humans under various
inﬂammatory conditions, for example following kidney
transplantation,50 nematode infection51 or pulmonary ﬁbro-
sis.52 By contrast, although TEM display a hemangiogenic
character (26 and Fig. 2), they were not found to be inserted
into the blood vessels of breast tumor. TEM are enriched
into tumor zones containing newly formed and poorly
structured blood vascular network (Figs. 4A and B), thus
emphasizing their role in the early phase of tumor vascular-
ization and growth (Fig. 2).
We propose that the breast tumor microenvironment
may shape TEM phenotype and function. Indeed, as com-
pared to tumor-inﬁltrating TEM, CD14C cells in adjacent
Figure 6. TEM lymphangiogenic activity is supported by cross-talk between VEGFR and TIE-2 pathways. (A) In vivo corneal vascularization assay was used to assess the
lymphangiogenic activity of TEM isolated from human breast tumors. Lymphatic vessels emerging from the peripheral limbal vasculature were labeled with LYVE-1-spe-
ciﬁc antibodies in sagittal sections of mouse eyes. Double-headed and single arrows depict cornea and iris respectively. Scale bar: 100 mm; (B) Confocal microscopy
images of TEM sorted from dissociated breast tumor showing expression of VEGF-A, -C and -D. Scale bar: 5mm; (C) TEM isolated from dissociated breast tumors were
exposed to TIE-2- and VEGFR-speciﬁc kinase inhibitors and their hem- and lymphangiogenic activities were measured in vitro using a sprouting assay of HUVEC and LEC
respectively (t test,  p <0.001,  p < 0.0001).
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non-neoplastic breast tissue expressed much lower levels of
TIE-2 and VEGFR-1 (Fig. 1E), and no detectable levels of
Podoplanin and VEGFR-3 (Fig. 3E). This observation sug-
gests that the LEC phenotype and TIE-2 expression are
acquired by TEM following their inﬁltration into the tumor.
The acquisition of a TEM phenotype coincided with the
association of TEM with tumor lymphatics (Figs. 5A, B and
Figs. S6A and B), while TEM were absent from lymphatic
vessels in adjacent non-neoplastic tissue (Fig. 5C and
Fig. S6C), suggesting that the breast tumor microenviron-
ment shapes both TEM phenotype and spatial distribution.
In cervix cancer, TAM displaying traits of LEC were
observed in close proximity but not inserted into lymphatic
vessels30 supporting the hypothesis that distinct tumor
microenvironments induce different TAM phenotype and
spatial distribution.
Our study comprised a low number of BC, the majority of
which were of luminal histological subtype (Table 2). We found
that the levels of TEM inﬁltration tended to increase in high histo-
logical grade tumors and correlated with tumor size.26 Our obser-
vations are consistent with previous studies where larger numbers
of BC were examined and that reported that higher levels of
monocyte inﬁltration is associated with poor prognosis, high his-
tological tumor grade53-55 and LNmetastasis.56
Finally, TEM dual hem- and lymphangiogenic activities
are synergistically controlled by TIE-2 and VEGFR path-
ways27 and impaired by combined treatment with TIE-2
and VEGFR kinase inhibitors (Fig 6C). This result may
explain the limited efﬁcacy of VEGF-A neutralizing anti-
body in TEM hemangiogenic activity27 and in the treatment
of BC.57 Furthermore, our results suggest rather that com-
bined inhibition of VEGFR and TIE-2 kinase activities con-
sistently overcame TEM intrinsic resistance mechanisms in
untreated BC patients (Fig. 6C). Importantly, we previously
reported that BC-associated TEMs are plastic cells that can
be reverted from suppressive, hemangiogenic cells into cells
that are able to mediate an antitumoral immune response
by inhibition of the TIE-2 and VEGFR pathways.27 Taken
together, our results show that lymphangiogenic, hemangio-
genic and suppressive functions of TEMs are similarly
driven by TIE-2 and VEGFR kinase pathways which may
represent attractive therapeutic targets in BC.
Materials and methods
Detailed material and methods are reported in supplementary
material and methods.
Cells and tissue specimens
This study was approved by the ethics committee of the Uni-
versity Hospital (CHUV) of Lausanne, Switzerland. Patient tis-
sue specimens were obtained according to the declaration of
Helsinki and upon written informed consent. Invasive ductal
breast carcinomas were resected from untreated patients
(Table 1). All characterization and assays were performed using
tumor specimens from the viable (non-necrotic) tumor center,
and excluding most of the peritumoral non-neoplastic tissues.
Tumor tissues were freshly dissociated enzymatically with 0.1%
collagenase I (Worthington, Lakewood, NJ) for 40 min at 37C.
HUVEC (Human Umbilical Vein Endothelial Cells) and LEC
(human dermal lymphatic microvascular endothelial cells)
from adult were from Lonza (Basel, Switzerland).
Reagents and antibodies
Chemicals were from Sigma-Aldrich (St. Louis, MO) unless
indicated otherwise. TIE-2 inhibitor compound 7 was from
Alexis Biochemicals (San Diego, CA) and VEGFR inhibitor
PTK787 from Novartis Institutes for BioMedical Research
(Basel, Switzerland). Antibodies are described in supplementary
material and methods.
In vivo and in vitro angiogenic assays
The assays were performed as described.26,27, 58 Detailed proce-
dure can be found in supplementary material and methods.
Animals and establishment of patient-derived BC
xenografts
About 12 fragments of patient tumor (3.35 mm3) were embed-
ded in matrigel and grafted subcutaneously into NOD-scid
IL2Rgnull (NSG) mice. Mice received b-estradiol (8.5 mg/mL)
diluted in drinking water and xenografts larger than 1mm3
developed 3 months later in 20% of the mice. Mice with compa-
rable tumor size were used and 20,000 tumor TEM isolated by
positive immunomagnetic selection (from frozen viable dissoci-
ated tumors of the same patient) or beads only were injected in
the tumor vicinity of test and control mice, respectively. Two
weeks later, the mice were sacriﬁced, the tumors were embed-
ded in OCT and sectioned every 0.2 mm. All the sections were
stained for CD31 and the vascular network quantiﬁed by epi-
ﬂuorescence microscopy.
Table 2. Pathological features of the tumors used for each experiment.
Parameter examined Figures Luminal A Luminal B Triple Neg. HER2Enriched Total
Correlation CD14_TIE2_VEGFR1 1, S1 and S3 4 5 1 1 11
TEM angiogenic activity in PDX models 2 3 0 0 0 3
TEM express LEC markers 2, 3, S4 and S5 4 6 1 0 11
TEM and blood Vascular network 4 6 7 2 1 16
TEM association with lymphatics(among which LN metastasis) 5 and S6 12(6/12) 14(5/14) 5(3/5) 00 22
Lymphangiogenic activity 6 1 4 2 0 7
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Histology, confocal microscopy and image quantiﬁcation
Frozen primary BC specimen were cut in 6 mm sections,
stained and imaged as previously described.27 Receptors coloc-
alization was examined using a custom algorithm written in C
as detailed in supplemental methods and available upon
request.
Statistical analyses
Statistical analyses (two-tailed Student’s t test) were performed
using GraphPad Prism version 4.00 for Windows (GraphPad
Software, San Diego, CA). Results were considered to be signiﬁ-
cant with  p < 0.05;  p < 0.01;  p < 0.001,  p < 0.0001.
Spearman’s rank correlation coefﬁcients were calculated using R.
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